Amit Etkin - Feb 1, 2024 Form 3 Insider Report for Alto Neuroscience, Inc. (ANRO)

Role: President and CEO, Director
Signature: /s/ Erin R. McQuade, Attorney-in-Fact
Stock symbol: ANRO
Transactions as of: Feb 1, 2024
Transactions value $: $0
Form type: 3
Date filed: 2/1/2024, 06:52 PM
Next filing: Feb 7, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	ANRO	Common Stock						1.19M	Feb 1, 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	ANRO	Series B Preferred Stock							Feb 1, 2024	Common Stock	11.8K		Direct	F2
holding	ANRO	Employee Stock Option (Right to Buy)							Feb 1, 2024	Common Stock	157K	$2.32	Direct	F3
holding	ANRO	Employee Stock Option (Right to Buy)							Feb 1, 2024	Common Stock	34.6K	$6.23	Direct	F4
holding	ANRO	Employee Stock Option (Right to Buy)							Feb 1, 2024	Common Stock	247K	$5.30	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes a Restricted Stock Award ("RSA") of 202,329 shares. 25% of the shares vested on May 27, 2021, and one forty-eighth (1/48th) of the shares vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.
F2	Each share of Series B Preferred Stock is convertible at any time, at the holder's election, and will automatically convert into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.1226069 for 1 basis into the number of shares of Common Stock shown in column 3 and has no expiration date.
F3	The shares subject to the option are fully vested and exercisable.
F4	25% of the shares underlying the option vested on January 1, 2024, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.
F5	One-third (1/3rd) of the shares underlying the option shall vest upon the completion of the Issuer's initial public offering and two-thirds (2/3) of the shares underlying the option shall vest over a period of four years, with 25% of the shares underlying the time-based portion vesting on December 20, 2024, and 1/48 of the shares underlying the time-based portion vesting on a monthly basis thereafter, subject to the Reporting Person's continuous service through such vesting date.